Insider Trading Alert - MWV, RSG And ALXN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Sept. 26, 2014, 22 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $3,894.00 to $9,906,900.00.

Highlighted Stocks Traded by Insiders:

MeadWestvaco (MWV) - FREE Research Report

Cox Donna O, who is Vice President - Communication at MeadWestvaco, sold 7,590 shares at $41.19 on Sept. 26, 2014. Following this transaction, the Vice President - Communication owned 10,562 shares meaning that the stake was reduced by 41.81% with the 7,590-share transaction.

The shares most recently traded at $41.00, down $0.19, or 0.46% since the insider transaction. Historical insider transactions for MeadWestvaco go as follows:

  • 4-Week # shares sold: 1,489
  • 12-Week # shares sold: 745
  • 24-Week # shares sold: 745

The average volume for MeadWestvaco has been 816,100 shares per day over the past 30 days. MeadWestvaco has a market cap of $6.9 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 12.02% year-to-date as of the close of trading on Friday.

MeadWestvaco Corporation provides packaging solutions to healthcare, beauty and personal care, food, beverage, home and garden, tobacco, and agricultural industries worldwide. The stock currently has a dividend yield of 2.44%. The company has a P/E ratio of 19.5. Currently, there are 3 analysts who rate MeadWestvaco a buy, 2 analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MWV - FREE

TheStreet Quant Ratings rates MeadWestvaco as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, increase in net income and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full MeadWestvaco Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Republic Services (RSG) - FREE Research Report

Cascade Investment Llc, who is 10% Owner at Republic Services, bought 5,000 shares at $39.39 on Sept. 26, 2014. Following this transaction, the 10% Owner owned 106.5 million shares meaning that the stake was boosted by 0% with the 5,000-share transaction.

The shares most recently traded at $38.72, down $0.67, or 1.73% since the insider transaction. Historical insider transactions for Republic Services go as follows:

  • 4-Week # shares bought: 4.3 million
  • 12-Week # shares bought: 13.1 million
  • 24-Week # shares bought: 16.9 million

The average volume for Republic Services has been 1.7 million shares per day over the past 30 days. Republic Services has a market cap of $13.9 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 17.5% year-to-date as of the close of trading on Friday.

Republic Services, Inc., together with its subsidiaries, provides non-hazardous solid waste collection, transfer, and recycling and disposal services for commercial, industrial, municipal, and residential customers in the United States and Puerto Rico. The stock currently has a dividend yield of 2.87%. The company has a P/E ratio of 19.6. Currently, there are 4 analysts who rate Republic Services a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RSG - FREE

TheStreet Quant Ratings rates Republic Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Republic Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Bell Leonard, who is Ceo at Alexion Pharmaceuticals, sold 60,000 shares at $165.12 on Sept. 26, 2014. Following this transaction, the Ceo owned 948,886 shares meaning that the stake was reduced by 5.95% with the 60,000-share transaction.

Squinto Stephen P, who is EVP, Chief Global Ops. Officer at Alexion Pharmaceuticals, sold 76 shares at $159.50 on Sept. 26, 2014. Following this transaction, the EVP, Chief Global Ops. Officer owned 106,868 shares meaning that the stake was reduced by 0.07% with the 76-share transaction.

The shares most recently traded at $165.46, up $5.96, or 3.6% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares sold: 12,692
  • 12-Week # shares sold: 28,469
  • 24-Week # shares sold: 33,279

The average volume for Alexion Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $32.8 billion and is part of the health care sector and drugs industry. Shares are up 26.16% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 83.3. Currently, there are 12 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens